J
John N. Galgiani
Researcher at University of Arizona
Publications - 239
Citations - 14410
John N. Galgiani is an academic researcher from University of Arizona. The author has contributed to research in topics: Coccidioides & Coccidioides immitis. The author has an hindex of 62, co-authored 226 publications receiving 13460 citations. Previous affiliations of John N. Galgiani include Merck & Co. & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
John H. Rex,Michael A. Pfaller,John N. Galgiani,Marilyn S. Bartlett,Ana Espinel-Ingroff,Mahmoud A. Ghannoum,M Lancaster,Frank C. Odds,Michael G. Rinaldi,Thomas J. Walsh,A L Barry +10 more
TL;DR: The conceptual framework underlying interpretation of antimicrobial susceptibility testing results is examined and these ideas are used to drive analysis of data packages developed by the respective manufacturers that correlate fluconazole and itraconazole MICs with outcome of candidal infections.
Journal ArticleDOI
NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
David W. Denning,David W. Denning,Jeanette Y. Lee,Jeanette Y. Lee,John S. Hostetler,John S. Hostetler,Peter G. Pappas,Peter G. Pappas,Carol A. Kauffman,Carol A. Kauffman,Daniel H. Dewsnup,Daniel H. Dewsnup,John N. Galgiani,John N. Galgiani,John R. Graybill,John R. Graybill,Alan M. Sugar,Alan M. Sugar,Antonino Catanzaro,Antonino Catanzaro,Harry A. Gallis,Harry A. Gallis,John R. Perfect,John R. Perfect,Bonita Dockery,Bonita Dockery,William E. Dismukes,William E. Dismukes,David A. Stevens,David A. Stevens +29 more
TL;DR: Oral itraconazole is a useful alternative therapy for invasive aspergillosis with response rates apparently comparable to amphotericin B, and relapse rates among those who completed therapy and those who discontinued early for possible toxicity were 12% and 40%, respectively.
Journal ArticleDOI
The role of understaffing in central venous catheter-associated bloodstream infections
TL;DR: Nursing staff reductions below a critical level, during a period of increased TPN use, may have contributed to the increase in CVC-BSI in the SICU by making adequate catheter care difficult.
Journal ArticleDOI
An insight into the antifungal pipeline: selected new molecules and beyond.
TL;DR: This Review focuses on recent developments in the antifungal pipeline, concentrating on promising candidates such as new azoles, polyenes and echinocandins, as well as agents such as nikkomycin Z and the sordarins.
Journal ArticleDOI
Antifungal susceptibility testing.
TL;DR: A standard method which minimizes interlaboratory variability during the testing of Candida spp.